S&P 500   4,292.76 (-1.03%)
DOW   33,723.64 (-0.83%)
QQQ   354.88 (-1.32%)
AAPL   172.71 (-1.91%)
MSFT   311.66 (-1.85%)
META   296.56 (-1.42%)
GOOGL   127.81 (-2.52%)
AMZN   127.16 (-3.13%)
TSLA   244.46 (-1.02%)
NVDA   420.78 (-0.34%)
NIO   8.35 (+0.00%)
BABA   86.12 (-1.26%)
AMD   96.49 (-0.91%)
T   14.94 (-0.80%)
F   12.50 (-0.64%)
MU   68.26 (-0.47%)
CGC   1.01 (+7.12%)
GE   110.95 (-0.69%)
DIS   80.10 (-1.12%)
AMC   8.20 (+0.74%)
PFE   32.69 (-0.88%)
PYPL   58.54 (-0.54%)
NFLX   380.98 (-0.99%)
S&P 500   4,292.76 (-1.03%)
DOW   33,723.64 (-0.83%)
QQQ   354.88 (-1.32%)
AAPL   172.71 (-1.91%)
MSFT   311.66 (-1.85%)
META   296.56 (-1.42%)
GOOGL   127.81 (-2.52%)
AMZN   127.16 (-3.13%)
TSLA   244.46 (-1.02%)
NVDA   420.78 (-0.34%)
NIO   8.35 (+0.00%)
BABA   86.12 (-1.26%)
AMD   96.49 (-0.91%)
T   14.94 (-0.80%)
F   12.50 (-0.64%)
MU   68.26 (-0.47%)
CGC   1.01 (+7.12%)
GE   110.95 (-0.69%)
DIS   80.10 (-1.12%)
AMC   8.20 (+0.74%)
PFE   32.69 (-0.88%)
PYPL   58.54 (-0.54%)
NFLX   380.98 (-0.99%)
S&P 500   4,292.76 (-1.03%)
DOW   33,723.64 (-0.83%)
QQQ   354.88 (-1.32%)
AAPL   172.71 (-1.91%)
MSFT   311.66 (-1.85%)
META   296.56 (-1.42%)
GOOGL   127.81 (-2.52%)
AMZN   127.16 (-3.13%)
TSLA   244.46 (-1.02%)
NVDA   420.78 (-0.34%)
NIO   8.35 (+0.00%)
BABA   86.12 (-1.26%)
AMD   96.49 (-0.91%)
T   14.94 (-0.80%)
F   12.50 (-0.64%)
MU   68.26 (-0.47%)
CGC   1.01 (+7.12%)
GE   110.95 (-0.69%)
DIS   80.10 (-1.12%)
AMC   8.20 (+0.74%)
PFE   32.69 (-0.88%)
PYPL   58.54 (-0.54%)
NFLX   380.98 (-0.99%)
S&P 500   4,292.76 (-1.03%)
DOW   33,723.64 (-0.83%)
QQQ   354.88 (-1.32%)
AAPL   172.71 (-1.91%)
MSFT   311.66 (-1.85%)
META   296.56 (-1.42%)
GOOGL   127.81 (-2.52%)
AMZN   127.16 (-3.13%)
TSLA   244.46 (-1.02%)
NVDA   420.78 (-0.34%)
NIO   8.35 (+0.00%)
BABA   86.12 (-1.26%)
AMD   96.49 (-0.91%)
T   14.94 (-0.80%)
F   12.50 (-0.64%)
MU   68.26 (-0.47%)
CGC   1.01 (+7.12%)
GE   110.95 (-0.69%)
DIS   80.10 (-1.12%)
AMC   8.20 (+0.74%)
PFE   32.69 (-0.88%)
PYPL   58.54 (-0.54%)
NFLX   380.98 (-0.99%)
NYSE:BVS

Bioventus (BVS) Stock Forecast, Price & News

$2.94
-0.01 (-0.34%)
(As of 10:16 AM ET)
Compare
Today's Range
$2.89
$2.99
50-Day Range
$2.91
$4.94
52-Week Range
$0.80
$8.29
Volume
5,899 shs
Average Volume
824,487 shs
Market Capitalization
$231.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Bioventus MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
92.7% Upside
$5.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$854,928 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.83) to $0.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

254th out of 961 stocks

Surgical & Medical Instruments Industry

29th out of 98 stocks


BVS stock logo

About Bioventus (NYSE:BVS) Stock

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

BVS Price History

BVS Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Bioventus works to trim debt under interim CEO
2BVS : Bioventus Earnings Preview
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Recap: Bioventus Q1 Earnings
Bioventus Reports First Quarter Financial Results
7BVS : Earnings Preview: Bioventus
See More Headlines
Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

BVS Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/20/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,120
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+92.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-158,700,000.00
Pretax Margin
-67.05%

Debt

Sales & Book Value

Annual Sales
$510.62 million
Cash Flow
$1.67 per share
Book Value
$4.37 per share

Miscellaneous

Free Float
55,713,000
Market Cap
$231.81 million
Optionable
Not Optionable
Beta
0.34
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Mark L. Singleton (Age 53)
    Sr. VP & CFO
    Comp: $444.12k
  • Mr. Anthony P. Bihl III (Age 67)
    CEO & Director
  • Mr. David Crawford
    VP of Investor Relations & Treasurer
  • Mr. Anthony D'Adamio (Age 62)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Katrina J. Church J.D. (Age 61)
    Chief Compliance Officer
  • Ms. Helen Leupold
    Sr. VP & Chief HR Officer
  • Mr. Larry Chen
    Managing Director of China & Asia Pacific













BVS Stock - Frequently Asked Questions

Should I buy or sell Bioventus stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BVS, but not buy additional shares or sell existing shares.
View BVS analyst ratings
or view top-rated stocks.

What is Bioventus' stock price forecast for 2023?

4 Wall Street research analysts have issued 1-year target prices for Bioventus' shares. Their BVS share price forecasts range from $5.00 to $6.00. On average, they expect the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price.
View analysts price targets for BVS
or view top-rated stocks among Wall Street analysts.

How have BVS shares performed in 2023?

Bioventus' stock was trading at $2.61 at the start of the year. Since then, BVS stock has increased by 13.0% and is now trading at $2.95.
View the best growth stocks for 2023 here
.

When is Bioventus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023.
View our BVS earnings forecast
.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) issued its quarterly earnings results on Tuesday, August, 8th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.11. The business had revenue of $137.07 million for the quarter, compared to the consensus estimate of $128.90 million. Bioventus had a negative net margin of 55.42% and a positive trailing twelve-month return on equity of 1.24%.

What guidance has Bioventus issued on next quarter's earnings?

Bioventus updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of -$0.24--$0.20 for the period, compared to the consensus estimate of -$0.22. The company issued revenue guidance of $490.00 million-$505.00 million, compared to the consensus revenue estimate of $493.14 million.

When did Bioventus IPO?

(BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO.

What is Bioventus' stock symbol?

Bioventus trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVS."

Who are Bioventus' major shareholders?

Bioventus' stock is owned by a variety of institutional and retail investors. Top institutional investors include Juniper Investment Company LLC (8.51%), Kent Lake Capital LLC (1.15%), BlackRock Inc. (0.60%), Western Standard LLC (0.51%), Geode Capital Management LLC (0.44%) and Stephens Inc. AR (0.35%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins.
View institutional ownership trends
.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioventus' stock price today?

One share of BVS stock can currently be purchased for approximately $2.95.

How much money does Bioventus make?

Bioventus (NYSE:BVS) has a market capitalization of $231.81 million and generates $510.62 million in revenue each year. The company earns $-158,700,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis.

How many employees does Bioventus have?

The company employs 1,120 workers across the globe.

How can I contact Bioventus?

Bioventus' mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The official website for the company is www.bioventus.com. The company can be reached via phone at 919-474-6700 or via email at investor.relations@bioventus.com.

This page (NYSE:BVS) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -